LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced its financial results for the fourth quarter and fiscal year 2024, ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced a strategic loan and security agreement with Hercules Capital, Inc. ...

Savara (SVRA) “announced encore presentations of top-line data from the pivotal, Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP will ...

March 27, 2025--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the ...

Swiss National Bank lessened its position in shares of Savara Inc (NASDAQ:SVRA – Free Report) by 6.7% during the fourth ...

LANGHORNE, Pa., March 26, 2025--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it ...

Savara (SVRA) announced that it has completed submission of the BLA to the FDA for MOLBREEVI as a treatment for aPAP. “Submission of the BLA ...

The latest price target for Savara (NASDAQ:SVRA) was reported by HC Wainwright & Co. on March 28, 2025. The analyst firm set a price target for $6.00 expecting SVRA to rise to within 12 months (a ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement ...